Risk-Adapted Approach to clinical trials and Risk Assessments

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides a strategic framework for implementing a risk-adapted approach to managing clinical trials involving Investigational Medicinal Products (IMPs). This guidance describes a two-part strategy designed to ensure participant safety and data integrity through proportionate oversight. The first component involves stratifying trials into three categories (Type A, B, or C) based on the marketing authorization status and inherent risks of the IMP. This classification determines the specific MHRA authorization requirements, documentation standards, and safety monitoring plans. The second component is a bespoke, trial-specific risk assessment aimed at identifying vulnerabilities in conduct that could jeopardize participant rights or trial results. Under this regulatory framework, sponsors are expected to document mitigations for identified risks and may adapt traditional Good Clinical Practice (GCP) standards to fit the trial's risk profile. While the document serves as general guidance rather than an inspection report for a specific company or date, it mandates that sponsors perform comprehensive risk evaluations to develop tailored management and monitoring strategies. These actions ensure that regulatory resources and oversight are effectively focused on the areas of highest risk within clinical research.